We are proud to acknowledge the participation of Bayer’s Global Market Access team at this year’s Health Technology Assessment international (HTAi) annual meeting in Seville, Spain. With a symposium titled “Unlocking access to breakthrough treatments for patients with cancer”, HTA and payer attendees received updates on the value of patient access to Precision Oncology (PO). This event highlighted the clinical benefits and the need for access to genomic testing, which is the cornerstone for identifying patients who may benefit the most from such innovative treatments. Within this landscape, there are challenges, but also potential solutions like incorporating real-world evidence (RWE) into the HTA decision-making process. Thank you to each of our panelists, Merel Hennink Arnaud Bayle Nicola Normanno Yvonne-Beatrice Boehler, Prof., MD, MBA and moderator, Clifford Goodman for contributing to an insightful and successful session.
Bayer | Oncology
Pharmaceutical Manufacturing
At Bayer, we’re committed to a patient-centered approach to cancer care & are focused on innovation & change in oncology
About us
Over the last 20 years, the cancer treatment landscape has seen significant progress. However, there is still much work to be done to help the those living with cancer across the globe. With recent innovations in difficult-to-treat tumors, Bayer is at the forefront of the evolving global oncology landscape. At Bayer, we’re committed to a patient-centered approach to cancer care and are continuously working to bring about innovation and change in oncology. This channel is dedicated exclusively to oncology and all those impacted by the disease. We invite you to join us on this journey.
- Website
-
https://www.oncology.bayer.com/
External link for Bayer | Oncology
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
Updates
-
Congratulations to all Bayer colleagues and external experts involved in the third Global Oncology Access Leadership (GOAL) steering committee meeting in Berlin in June. GOAL was established to identify and tackle access challenges to innovative prostate cancer treatments by ensuring timely dialogue and engagement with thought leaders. We are grateful to all committee members for their time and highly valuable input provided during the meeting. #PatientAccess #Oncology #ProstateCancer #Stakeholderengagement
-
-
Bayer Oncology will be attending the American Society of Clinical Oncology (ASCO)'s 2024 Congress in Chicago, Illinois! 🙌 Learn more about Bayer’s exciting pipeline and mission in precision oncology by visiting our medical booth (#17078). More information can also be found on the Oncology Pipeline website: https://lnkd.in/epQVV_xF #ASCO24 #CancerResearch #PrecisionOncology
-
The value and impact of real-world evidence is becoming more apparent as RWE is used to address gaps in knowledge and complement evidence from clinical trials in recent years. Real-world evidence: 🔬 Provides information on patients who are underrepresented or excluded from clinical trials” 🩺 Optimizes patient management in a broad population reflective of routine clinical practice 🤔 Supports everyday clinical decision-making Learn more in our latest brochure, with valuable contributions from 'Afsaneh Barzi' and Pedro Uson: https://go.bayer.com/rwe24 #RealWorldEvidence #RWE #ClinicalTrials
-
Research To Practice will be hosting a hybrid symposium on the management of prostate cancer in conjunction with #ASCO24! The expert panel will be discussing: 📕 Optimizing the management of #nmCRPC 📕 Evidence-based selection of treatment for #mHSPC 📕 New considerations with the use of PARP inhibitors in #mCRPC 📕 Role of novel radiopharmaceuticals for mCRPC 📕 Promising investigational approaches for patients with prostate cancer Learn more and register here: https://lnkd.in/eqf7X-ez Available for CME credit.
-
-
New data and collaborative patient management are key in shaping personalized treatment in prostate cancer. Join this symposium organized by PVI, PeerView Institute for Medical Education to hear from expert panellists: 🩺 Karim Fizazi, MD, PhD 🩺 Pedro C Barata, MD MSc FACP 🩺 Kim N. Chi, MD, FRCPC 🩺 Alicia K. Morgans, MD, MPH The panel will discuss strategies for developing treatment protocols that incorporate treatment intensification for patients with prostate cancer. They will also explore improving collaboration with colleagues to prevent and manage adverse events associated with contemporary treatment regimens. Available for CME credit. Register here: https://lnkd.in/e5QRUWYU #ProstateCancer #MedEd #MedicalEducation
-
-
GI CONNECT celebrates 10 years! 🎉 Bayer is proud to support programs that reach 54,000 healthcare professionals in 30 countries. Here’s to many more years! Learn more: https://lnkd.in/eg8NTU_Q #MedEd #GICancer COR2ED
We are celebrating our 10 year anniversary here at GI CONNECT! Our international group of experts have supported, and continue to support HCPs in the fight against GI cancers with our innovative educational programs designed to challenge and inspire. Transforming complex and ever-evolving data into digestible learning that slots into the busy lives of HCPs, we have created a range of podcasts, interactive case studies, meeting reports, and more. We connect GI experts to each other whilst helping to translate clinical data into clinical practice to improve patient's lives.
-
#AACR24: Explore the preclinical results of a targeted radionuclide therapy in metastatic prostate cancer. Abstract 6033, Poster Session #CancerResearch #ProstateCancer American Association for Cancer Research
-
-
#AACR24: Learn preclinical results from a targeted radionuclide therapy in metastatic, castration-resistant prostate cancer. Abstract ND09, Oral Presentation #mCRPC #CancerResearch American Association for Cancer Research
-
-
#AACR24: discover preclinical results of a targeted alpha therapy and androgen receptor inhibitor in prostate cancer. Abstract 688, Poster Session #ProstateCancer #CancerResearch American Association for Cancer Research
-